Investor Presentaiton
Key priorities for the upcoming quarters:
India
1
2
3
4
Cipla
Leverage on the momentum and continue to drive performance across both prescription and
generics
。 Execute on the One-India strategy leveraging synergies across the 3 businesses
South Africa
Continue growth momentum in the private market portfolio to deliver growth in the overall
business
Continue to be a dominant player in the OTC space and drive further growth in the Mirren portfolio
US:
Focus on maximizing value opportunity in key commercial assets
Continue to track Respiratory filings closely; focused investments going forward
Finalize out-licensing for CNS Specialty assets
Quality and Compliance
Work with US FDA to comprehensively address the observations in Goa
Continue to operate our facilities globally with the highest level of compliance and control
Investor Presentation: Q3FY20
12View entire presentation